贝伐单抗治疗结直肠癌患者期间的晚期吻合口裂开 - Suppr | 超能文献

Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.

作者信息

Garant A, Des Groseilliers S, Martin L, Ferland É, Vuong T

出版信息

Clin Oncol (R Coll Radiol). 2011 Sep;23(7):497-8. doi: 10.1016/j.clon.2011.03.009. Epub 2011 May 14.

DOI:10.1016/j.clon.2011.03.009

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.贝伐单抗治疗结直肠癌患者期间的晚期吻合口裂开

Clin Oncol (R Coll Radiol). 2011 Sep;23(7):497-8. doi: 10.1016/j.clon.2011.03.009. Epub 2011 May 14.

2

Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.FOLFOXIRI联合贝伐单抗治疗后的肝切除术：详细病理回顾

Br J Cancer. 2013 Jun 25;108(12):2417-8. doi: 10.1038/bjc.2013.244.

3

Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.转移性结直肠癌的多药联合方案：如果说部分有效就不错，那么更多药物联合肯定更好。

J Natl Cancer Inst. 2011 Jan 5;103(1):4-5. doi: 10.1093/jnci/djq483. Epub 2010 Dec 1.

4

[Incidence and management of adverse events in FOLFOX plus bevacizumab therapy for colorectal cancer].

Nihon Rinsho. 2015 Feb;73 Suppl 2:582-6.

5

Common side effects and interactions of colorectal cancer therapeutic agents.结直肠癌治疗药物的常见副作用及相互作用。

J Pract Nurs. 2011 Spring;61(1):7-20.

6

Bevacizumab in the treatment of colorectal cancer.贝伐单抗用于治疗结直肠癌。

Clin Adv Hematol Oncol. 2007 Jan;5(1 Suppl 1):8-9.

7

Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.标准化疗联合贝伐珠单抗治疗的结直肠癌患者中 D-二聚体截断值＞3µg/ml 的治疗意义。

Jpn J Clin Oncol. 2010 Oct;40(10):933-7. doi: 10.1093/jjco/hyq058. Epub 2010 May 21.

8

First description of an uterine perforation potentially imputable to treatment with bevacizumab.首次描述了可能归因于贝伐单抗治疗的子宫穿孔。

Acta Oncol. 2012 Nov;51(8):1102-4. doi: 10.3109/0284186X.2012.689855. Epub 2012 Oct 1.

9

[Progress of chemotherapy in colorectal cancer].

Gan To Kagaku Ryoho. 2007 Nov;34(11):1771-6.

10

Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.奥沙利铂联合羟基喜树碱与奥沙利铂联合5-氟尿嘧啶和亚叶酸钙治疗晚期结直肠癌的疗效比较

Chin Med J (Engl). 2006 Nov 5;119(21):1829-33.

引用本文的文献

1

Entero-Cutaneous and Entero-Atmospheric Fistulas: Insights into Management Using Negative Pressure Wound Therapy.肠皮肤瘘和肠-大气瘘：负压伤口治疗管理的见解

J Clin Med. 2024 Feb 23;13(5):1279. doi: 10.3390/jcm13051279.

2

Surgical complications of oncological treatments: A narrative review.肿瘤治疗的手术并发症：一篇叙述性综述。

World J Gastrointest Surg. 2023 Jun 27;15(6):1056-1067. doi: 10.4240/wjgs.v15.i6.1056.

3

Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases.结直肠癌患者中与贝伐单抗治疗相关的颌骨骨坏死延迟诊断：两例报告

Dent J (Basel). 2016 Oct 29;4(4):39. doi: 10.3390/dj4040039.